MAESTrO Snapshot Report - August 2018
Summary of the agenda for the PBAC March 2019 meeting
The PBAC will consider 58 submissions (29 major & 29 minor) at its next scheduled meeting in March (Table 1). Table 1. Submissions by technology type Technology category Number Percentage PBS medicine/vaccine/gene therapy 56 96 PBS medicinal preparation* 1 2 NIP vaccine 1 2 LSDP medicine** 0 0 PBS = Pharmaceutical Benefits Scheme; NIP = National Immunisation Program; LSDP = Life Saving Drugs Program. * Nutritional supplements; ** Section 100 or LSDP The Committee will consider two reports from the Drug Utilisation Subcommittee (DUSC) for medicines for: · Non-Hodgkin’s lymphoma (1 medicine) · Haemolytic uraemic syndrome (1 medicine) The PBAC will also consider matters relating to the post-market review of medicines for pulmonary arterial hypertension (8 medicines). 9 (16%) of the 58 submissions are for a new medicine (Table 2). Table 2. Submissions by listing type Listing type Number Percentage New medic
Comments
Post a Comment